Brensocatib Approval Highlights Potential of DPP1 Inhibitors for Neutrophil-Mediated Diseases: James D. Chalmers, MBChB, PhD
Written by
American Journal Managed Care
Published
0
comments
0
min
Brensocatib, the first FDA-approved dipeptidyl peptidase 1 (DPP1) inhibitor for non–cystic fibrosis bronchiectasis, may have broader potential for other neutrophil-driven conditions, according to James D. Chalmers, MBChB, PhD.